Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 3, Mars 2009
Page(s) 259 - 265
Section M/S revues
DOI https://doi.org/10.1051/medsci/2009253259
Publié en ligne 15 mars 2009
  1. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor : identity with interleukin 1 beta. J Immunol 1985; 135 : 2562–8.
  2. Miyamoto T, Ohneda O, Arai F, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001; 98 : 2544–54.
  3. Servet-Delprat C, Arnaud S, Jurdic P, et al. Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol 2002; 24 : 3:15.
  4. Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408 : 535–6.
  5. Pettit AR, Ji H, von Stechow D,et al.TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159 : 1689–99.
  6. Redlich K, Hayer S, Ricci R,et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110 : 1419–27.
  7. Solari F, Jurdic P. Nouveaux concepts sur l’origine des ostéoclastes : relation avec les macrophages normaux et inflammatoires. Med Sci (Paris) 1997; 13 : 1285–93.
  8. Rivollier A, Mazzorana M, Tebib J, et al. Immature dendritic cell transdifferentiation into osteoclasts : a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004; 104 : 4029–37.
  9. Alnaeeli M, Penninger JM, Teng YT. Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. J Immunol 2006; 177 : 3314–26.
  10. Speziani C, Rivollier A, Gallois A, et al. Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines. Eur J Immunol 2007; 37 : 747–57.
  11. Wakkach A, Mansour A, Dacquin R, et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008; 112 : 5074–83.
  12. Xing L, Schwarz EM, Boyce BF Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005; 208 : 19–29.
  13. Coury F, Annels N, Rivollier A, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 14 : 81–7.
  14. Marie P, Halbout P OPG/RANKL : implication et cible thérapeutique dans l’ostéoporose. Med Sci (Paris) 2008; 24 : 105–10.
  15. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96 : 3540–5.
  16. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390 : 175–9.
  17. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000; 97 : 10905–10.
  18. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397 : 315–23.
  19. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development.Genes Dev 1999; 18 : 2412–24.
  20. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin : a novel secreted protein involved in the regulation of bone density. Cell 1997; 89 : 309–19.
  21. Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001; 166 : 1482–91.
  22. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43 : 259–69.
  23. Crotti TN, Smith MD, Weedon H, et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients : semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61 : 1047–54.
  24. Haynes DR, Barg E, Crotti TN, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003; 42 : 123–34.
  25. Paloneva J, Mandelin J, Kiialainen A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 2003; 198 : 669–75.
  26. Kaifu T, Nakahara J, Inui M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003; 111 : 323–32.
  27. Nataf S, Anginot A, Vuaillat C, et al. Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol 2005; 166 : 275–86.
  28. Mócsai A, Humphrey MB, Van Ziffle JA,et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004; 101 : 6158–63.
  29. Colonna M, Turnbull I, Klesney-Tait J. The enigmatic function of TREM-2 in osteoclastogenesis. Adv Exp Med Biol 2007; 602 : 97–105.
  30. Shinohara M, Koga T, Okamoto K, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 2008; 132 : 794–806.
  31. Lee SH, Kim T, Jeong D, et al. The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation. J Biol Chem 2008; 283 : 11526–34.
  32. Anginot A, Dacquin R, Mazzorana M, Jurdic P. Lymphocytes and the Dap12 adaptor are key regulators of osteoclast activation associated with gonadal failure. PLoS One 2007; 2 : e585.
  33. Wu Y, Torchia J, Yao W, et al. Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen-deficiency. PLoS One 2007; 2 : e586.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.